Executive Change · Reg FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) – March 2, 2018 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter)           Pennsylvania   1-8036   23-1210010 (State or other jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)           530 Herman O. West Drive, Exton, PA       19341-0645 (Address of principal executive offices)       (Zip Code)  Registrant’s telephone number, including area code: 610-594-2900 Not Applicable (Former name or address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨   1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 2, 2018, William J. Federici, Senior Vice President, Chief Financial Officer & Treasurer, announced his intention to retire later this year. Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.1 and incorporated by reference herein is a press release dated March 2, 2018 issued by the Company. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ( “ Exchange Act ” ), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description    99.1 West Pharmaceutical Services, Inc. Press Release, dated March 2, 2018. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   WEST PHARMACEUTICAL SERVICES, INC.                 /s/ George L. Miller      George L. Miller      Senior Vice President, General Counsel & Corporate      Secretary         March 2, 2018     3 EXHIBIT INDEX Exhibit No.   Description 99.1   West Pharmaceutical Services, Inc. Press Release, dated March 2, 2018. 4